Head and Neck

May 12, 2021

Immunovirotherapy with oncolytic HSV-1 G207 shows promising tumor response in pediatric high-grade glioma

Clinical outcomes in children and adolescents with recurrent or progressing high-grade glioma are poor. The  median overall survival is approximately five months   Pediatric high-grade gliomas are immunologically silent or […]
July 22, 2019

FDA approves pembrolizumab for first-line treatment of head and neck squamous cell carcinoma

On June 10, the Food and Drug Administration (FDA) approved Keytruda (pembrolizumab) in the first-line setting as monotherapy for patients whose tumors express PD-L1 or in […]
May 21, 2019

JAMA HPV study relates persistent tumor with the worst prognosis in scope of head and neck

DNA detection of persistent oral human papillomavirus (HPV) may be associated with recurrence of squamous cell carcinoma of the head and neck positive for HPV (HNSCC). […]